Anti-Cx43 Antibody Formulation for Aqueous Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Challenges exist in stabilizing anti-Cx43 antibodies for transport and storage, as they are prone to denaturation, aggregation, and particle formation, and existing formulations are not universally applicable across different antibodies.
Innovation Solution
A stable, aqueous pharmaceutical formulation comprising anti-Cx43 antibodies with specific CDR sequences, histidine/histidine hydrochloride buffer, polysorbate 80, and sucrose, maintained at a pH of 5 to 6, which enhances stability and prevents aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If antibodies are stored in aqueous formulations, then ease of operation is improved, but stability deteriorates due to denaturation, aggregation, and particle formation
Solution Approach 1:
The patent applies parameter changes by optimizing the pH of the aqueous formulation to between 5.0 and 6.5, which is lower than conventional formulations. This pH adjustment, combined with specific buffer selection (acetate, citrate, or phosphate buffers), stabilizes the antibody structure in aqueous solution, preventing denaturation and aggregation while maintaining ease of administration without lyophilization
Solution Approach 2:
The patent uses composite materials by combining the antibody with a specific formulation system consisting of buffers (acetate, citrate, or phosphate), surfactants (polysorbate 20, polysorbate 80, or poloxamer 188), and stabilizers (sugars like sucrose or trehalose, or amino acids like arginine or glycine). This composite formulation provides both aqueous stability and operational ease
2Stability of the object's composition
If lyophilization is used to stabilize antibodies, then stability is improved, but device complexity increases due to additional reconstitution steps
Solution Approach 1:
The patent extracts the need for lyophilization by developing a stable aqueous formulation that maintains antibody integrity without freeze-drying. The formulation achieves this through pH optimization (5.0-6.5), specific buffer selection, and inclusion of stabilizing excipients, thereby eliminating the reconstitution step and simplifying the administration process while maintaining stability
3Adaptability or versatility
If universal formulations are used for all antibodies, then adaptability is improved, but manufacturing precision deteriorates because optimal formulations are antibody-specific
Solution Approach 1:
The patent applies universality by providing a platform formulation system that can stabilize multiple different antibodies. The core formulation elements (pH 5.0-6.5 buffers, surfactants, and stabilizers) serve multiple functions and can be adapted to different antibody types, achieving both universality and manufacturing precision through systematic optimization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation maintains antibody stability and purity for extended periods, ensuring no significant changes at temperatures between -20°C and 8°C for up to 2 years, with improved stability and retention of biological activity.
Implementation Method 1
a buffer; wherein the pharmaceutical formulation has a pH of between about 5 and about 6
Implementation Method 2
a surfactant; Denaturation, aggregation, contamination, and particle formation can be significant obstacles in the formulation and storage of antibodies
Implementation Method 3
a stabilizer; wherein the pharmaceutical formulation maintains antibody stability and purity for extended periods
Data Source
AI summary
The present disclosure relates to pharmaceutical compositions and methods for treating a disease or condition associated with insufficient opening of Cx43 hemichannels in osteocytes, optionally for treating cancer, cancer metastasis, osteosarcoma, osteoporosis, or osteopenia.